Latest Advances

HER2-Positive Breast Cancer Treatments

• Tucatinib (Tukysa®) combined with Trastuzumab (Herceptin®) and Capecitabine (Xeloda®): Proven to improve outcomes and control CNS disease in HER2-positive patients with brain metastases.
• Trastuzumab Deruxtecan (Enhertu®): An antibody-drug conjugate showing strong CNS activity and extended progression-free survival in ongoing studies.

Triple-Negative Breast Cancer (TNBC) Treatments

• Sacituzumab Govitecan (Trodelvy®): FDA-approved antibody-drug conjugate with promising results in patients with metastatic TNBC, including those with brain metastases.
• Pembrolizumab (Keytruda®) and other PD-1/PD-L1 checkpoint inhibitors: Being explored in combination regimens for TNBC with CNS involvement.

HR-Positive / HER2-Negative Breast Cancer Treatments

• Abemaciclib (Verzenio®): A CDK4/6 inhibitor that may offer benefit for patients with hormone receptor-positive breast cancer and brain metastases.
• Alpelisib (Piqray®) and other PI3K inhibitors: Under clinical investigation for treating CNS progression in hormone-positive disease.

This is a rapidly evolving space. Ask your oncologist about clinical trials or newly approved therapies that may address brain metastases based on your breast cancer subtype.